{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:17Z","timestamp":1790958677393,"version":"4.1.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/100009377","name":"Hunan Provincial Department of Education Project","doi-asserted-by":"publisher","award":["21C0634"],"award-info":[{"award-number":["21C0634"]}],"id":[{"id":"10.13039\/100009377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background::<\/jats:title>\n                    <jats:p>This research intended to predict the active ingredients and key target genes of Indigo\nNaturalis in treating human chronic myeloid leukemia (CML) using network pharmacology and conduct the invitro\nverification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods::<\/jats:title>\n                    <jats:p>The active components of Indigo Naturalis and the corresponding targets and leukemia-associated\ngenes were gathered through public databases. The core targets and pathways of Indigo Naturalis were predicted\nthrough protein-protein interaction (PPI) network, gene ontology (GO) function, and Kyoto Encyclopedia of\nGenes and Genomes (KEGG) pathway enrichment analyses. Next, after intersecting with leukemia-related genes,\nthe direct core target gene of Indigo Naturalis active components was identified. Subsequently, HL-60 cells were\nstimulated with indirubin (IND) and then examined for cell proliferation using CCK-8 assay and cell cycle, cell\napoptosis, and mitochondrial membrane potential using flow cytometry. The content of apoptosis-associated\nproteins (Cleaved Caspase 9, Cleaved Caspase 7, Cleaved Caspase 3, and Cleaved parp) were detected using\nWestern blot, HSP90AA1 protein, and PI3K\/Akt signaling (PI3K, p-PI3K, Akt, and p-Akt) within HL-60 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results::<\/jats:title>\n                    <jats:p>A total of 9 active components of Indigo Naturalis were screened. The top 10 core target genes (TNF,\nPTGS2, RELA, MAPK14, IFNG, PPARG, NOS2, IKBKB, HSP90AA1, and NOS3) of Indigo Naturalis active\ncomponents within the PPI network were identified. According to the KEGG enrichment analysis, these targets\nwere associated with leukemia-related pathways (such as acute myeloid leukemia and CML). After intersecting\nwith leukemia-related genes, it was found that IND participated in the most pairs of target information and was at\nthe core of the target network; HSP90AA1 was the direct core gene of IND. Furthermore, the in-vitro cell experiments\nverified that IND could inhibit the proliferation, elicit G2\/M-phase cell cycle arrest, enhance the apoptosis\nof HL-60 cells, reduce mitochondrial membrane potential, and promote apoptosis-related protein levels. Under\nIND treatment, HSP90AA1 overexpression notably promoted cell proliferation and inhibited apoptosis. Additionally,\nIND exerted tumor suppressor effects on leukemia cells by inhibiting HSP90AA1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion::<\/jats:title>\n                    <jats:p>IND, an active component of Indigo Naturalis, could inhibit CML progression, which may be\nachieved via inhibiting HSP90AA1 and PI3K\/Akt signaling expression levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715206258293231017063340","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T02:37:20Z","timestamp":1707791840000},"page":"718-727","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Indirubin, an Active Component of Indigo Naturalis, Exhibits Inhibitory Effects on\nLeukemia Cells via Targeting HSP90AA1 and PI3K\/Akt Pathway"],"prefix":"10.2174","volume":"24","author":[{"given":"Yuanzhi","family":"Yao","sequence":"first","affiliation":[{"name":"College of Biology and Food Engineering, Huaihua University, Key Laboratory of Research and Utilization of Ethnomedicinal Plant\nResources of Hunan Province, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[{"name":"College of Biology and Food Engineering, Huaihua University, Key Laboratory of Research and Utilization of Ethnomedicinal Plant\nResources of Hunan Province, Huaihua 418000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Guizhou University of Traditional Chinese Medicine,\nGuiyang, 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Mou","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Guizhou University of Traditional Chinese Medicine,\nGuiyang, 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wei","sequence":"additional","affiliation":[{"name":"College of Biology and Food Engineering, Huaihua University, Key Laboratory of Research and Utilization of Ethnomedicinal Plant\nResources of Hunan Province, Huaihua 418000, China"},{"name":"College of Basic Medicine, Guizhou University of Traditional Chinese Medicine,\nGuiyang, 550025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.2147\/CMAR.S166859","volume":"10","author":"Li Z.","year":"2018","unstructured":"Li Z.; Luo J.; Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia. Cancer Manag Res  2018,10,5349-5362","journal-title":"Cancer Manag Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"Jabbour E.","year":"2022","unstructured":"Jabbour E.; Kantarjian H.; Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol  2022,97(9),1236-1256","journal-title":"Am J Hematol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/14656566.2019.1599357","volume":"20","author":"Shallis R.M.","year":"2019","unstructured":"Shallis R.M.; Podoltsev N.; What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly? Expert Opin Pharmacother  2019,20(10),1169-1173","journal-title":"Expert Opin Pharmacother"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"Deininger M.","year":"2005","unstructured":"Deininger M.; Buchdunger E.; Druker B.J.; The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood  2005,105(7),2640-2653","journal-title":"Blood"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","volume":"24","author":"Meenakshi Sundaram D.N.","year":"2019","unstructured":"Meenakshi Sundaram D.N.; Jiang X.; Brandwein J.M.; Valencia-Serna J.; Remant K.C.; Uluda\u011f H.; Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today  2019,24(7),1355-1369","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"17239","DOI":"10.1002\/cam4.6296","volume":"12","author":"Chen Y.","year":"2023","unstructured":"Chen Y.; Xu N.; Yang Y.; Liu Z.; Xue M.; Meng L.; He Q.; Chen C.; Zeng Q.; Zhu H.; Du X.; Zou J.; He W.; Guo J.; Chen S.; Yuan G.; Wu H.; Hong M.; Cheng F.; Liu B.; Zhang Y.; Li W.; Quality of life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med  2023,12(16),17239-17252","journal-title":"Cancer Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"Soverini S.","year":"2018","unstructured":"Soverini S.; Mancini M.; Bavaro L.; Cavo M.; Martinelli G.; Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer  2018,17(1),49","journal-title":"Mol Cancer"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/1750-3841.14484","volume":"84","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Xiao Y.; Dong Q.; Ouyang W.; Qin Q.; Neferine in the lotus plumule potentiates the antitumor effect of imatinib in primary chronic myeloid leukemia cells in vitro. J Food Sci  2019,84(4),904-910","journal-title":"J Food Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3892\/etm.2021.10684","volume":"22","author":"Chen D.","year":"2021","unstructured":"Chen D.; Luo C.; Salidroside inhibits chronic myeloid leukemia cell proliferation and induces apoptosis by regulating the miR-140-5p\/wnt5a\/\u03b2-catenin axis. Exp Ther Med  2021,22(5),1249","journal-title":"Exp Ther Med"},{"key":"ref=10","first-page":"319","volume":"15","author":"McDermott L.","year":"2016","unstructured":"McDermott L.; Madan R.; Rupani R.; Siegel D.; A review of indigo naturalis as an alternative treatment for nail psoriasis. J Drugs Dermatol  2016,15(3),319-323","journal-title":"J Drugs Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00535-016-1292-z","volume":"52","author":"Kawai S.","year":"2017","unstructured":"Kawai S.; Iijima H.; Shinzaki S.; Hiyama S.; Yamaguchi T.; Araki M.; Iwatani S.; Shiraishi E.; Mukai A.; Inoue T.; Hayashi Y.; Tsujii M.; Motooka D.; Nakamura S.; Iida T.; Takehara T.; Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation. J Gastroenterol  2017,52(8),904-919","journal-title":"J Gastroenterol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"115522","DOI":"10.1016\/j.jep.2022.115522","volume":"297","author":"Zhang Q.","year":"2022","unstructured":"Zhang Q.; Xie J.; Li G.; Wang F.; Lin J.; Yang M.; Du A.; Zhang D.; Han L.; Psoriasis treatment using Indigo Naturalis: Progress and strategy. J Ethnopharmacol  2022,297,115522","journal-title":"J Ethnopharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13020-020-00415-w","volume":"15","author":"Tu P.","year":"2020","unstructured":"Tu P.; Tian R.; Lu Y.; Zhang Y.; Zhu H.; Ling L.; Li H.; Chen D.; Beneficial effect of Indigo Naturalis on acute lung injury induced by influenza A virus. Chin Med  2020,15(1),128","journal-title":"Chin Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"597601","DOI":"10.3389\/fonc.2020.597601","volume":"10","author":"Lou Y.","year":"2021","unstructured":"Lou Y.; Ma Y.; Jin J.; Zhu H.; Oral realgar-indigo naturalis formula plus retinoic acid for acute promyelocytic leukemia. Front Oncol  2021,10,597601","journal-title":"Front Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e5216","DOI":"10.1002\/bmc.5216","volume":"35","author":"Huang H.","year":"2021","unstructured":"Huang H.; Li Y.; Dai Y.; Zhang Y.; Lu Q.; Xu Q.; Zhang Y.; Antileukemic effects of indigo naturalis constituents by \u201ctarget constituent knock out\u201d coupled with semipreparative liquid chromatography and quadrupole time of flight mass spectrometry. Biomed Chromatogr  2021,35(12),e5216","journal-title":"Biomed Chromatogr"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"682862","DOI":"10.3389\/fchem.2021.682862","volume":"9","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Zhang Y.; Wang Y.; Shu X.; Lu C.; Shao S.; Liu X.; Yang C.; Luo J.; Du Q.; Using network pharmacology and molecular docking to explore the mechanism of Shan Ci Gu (Cremastra appendiculata) against non-small cell lung cancer. Front Chem  2021,9,682862","journal-title":"Front Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.12659\/MSM.908756","volume":"24","author":"Li H.","year":"2018","unstructured":"Li H.; Liu L.; Liu C.; Zhuang J.; Zhou C.; Yang J.; Gao C.; Liu G.; Lv Q.; Sun C.; Deciphering key pharmacological pathways of qingdai acting on chronic myeloid leukemia using a network pharmacology-based strategy. Med Sci Monit  2018,24,5668-5688","journal-title":"Med Sci Monit"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.12659\/MSM.908104","volume":"24","author":"Zhou C.","year":"2018","unstructured":"Zhou C.; Liu L.; Zhuang J.; Wei J.; Zhang T.; Gao C.; Liu C.; Li H.; Si H.; Sun C.; A systems biology-based approach to uncovering molecular mechanisms underlying effects of traditional Chinese medicine Qingdai in chronic myelogenous leukemia, involving integration of network pharmacology and molecular docking technology. Med Sci Monit  2018,24,4305-4316","journal-title":"Med Sci Monit"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"113112","DOI":"10.1016\/j.biopha.2022.113112","volume":"151","author":"Yang L.","year":"2022","unstructured":"Yang L.; Pharmacological properties of indirubin and its derivatives. Biomed Pharmacother  2022,151,113112","journal-title":"Biomed Pharmacother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.3390\/ijms13066964","volume":"13","author":"Xu X.","year":"2012","unstructured":"Xu X.; Zhang W.; Huang C.; Li Y.; Yu H.; Wang Y.; Duan J.; Ling Y.; A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci  2012,13(6),6964-6982","journal-title":"Int J Mol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"Szklarczyk D.","year":"2023","unstructured":"Szklarczyk D.; Kirsch R.; Koutrouli M.; Nastou K.; Mehryary F.; Hachilif R.; Gable A.L.; Fang T.; Doncheva N.T.; Pyysalo S.; Bork P.; Jensen L.J.; von Mering C.; The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res  2023,51(D1),D638-D646","journal-title":"Nucleic Acids Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"baq020","DOI":"10.1093\/database\/baq020","volume":"2010","author":"Safran M.","year":"2010","unstructured":"Safran M.; GeneCards Version 3: The human gene integrator. Database  2010,2010,baq020","journal-title":"Database"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1111\/cas.13830","volume":"109","author":"Xie L.","year":"2018","unstructured":"Xie L.; Shi F.; Tan Z.; Li Y.; Bode A.M.; Cao Y.; Mitochondrial network structure homeostasis and cell death. Cancer Sci  2018,109(12),3686-3694","journal-title":"Cancer Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"174633","DOI":"10.1016\/j.ejphar.2021.174633","volume":"913","author":"Ding L.","year":"2021","unstructured":"Ding L.; Chen Q.; Chen K.; Jiang Y.; Li G.; Chen Q.; Bai D.; Gao D.; Deng M.; Zhang H.; Xu B.; Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K\/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol  2021,913,174633","journal-title":"Eur J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cbin.10989","volume":"42","author":"Li L.","year":"2018","unstructured":"Li L.; Qi Y.; Ma X.; Xiong G.; Wang L.; Bao C.; TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K\/Akt\/mTOR signaling pathway. Cell Biol Int  2018,42(9),1192-1199","journal-title":"Cell Biol Int"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/cancers13081770","volume":"13","author":"Sch\u00e4fer M.","year":"2021","unstructured":"Sch\u00e4fer M.; Semmler M.L.; Bernhardt T.; Fischer T.; Kakkassery V.; Ramer R.; Hein M.; Bekeschus S.; Langer P.; Hinz B.; Emmert S.; Boeckmann L.; Small molecules in the treatment of squamous cell carcinomas: Focus on indirubins. Cancers (Basel)  2021,13(8),1770","journal-title":"Cancers (Basel)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2018.09.023","volume":"839","author":"Lee M.Y.","year":"2018","unstructured":"Lee M.Y.; Li Y.Z.; Huang K.J.; Huang H.C.; Lin C.Y.; Lee Y.R.; Indirubin-3\u2032-oxime suppresses human cholangiocarcinoma through cell-cycle arrest and apoptosis. Eur J Pharmacol  2018,839,57-65","journal-title":"Eur J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e12861","DOI":"10.1111\/jfbc.12861","volume":"43","author":"Rajagopalan P.","year":"2019","unstructured":"Rajagopalan P.; Dera A.; Abdalsamad M.R.; C Chandramoorthy H.; Rational combinations of indirubin and arylidene derivatives exhibit synergism in human non-small cell lung carcinoma cells. J Food Biochem  2019,43(7),e12861","journal-title":"J Food Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1054\/bjoc.2000.1546","volume":"84","author":"Marko D.","year":"2001","unstructured":"Marko D.; Sch\u00e4tzle S.; Friedel A.; Genzlinger A.; Zankl H.; Meijer L.; Eisenbrand G.; Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer  2001,84(2),283-289","journal-title":"Br J Cancer"},{"key":"ref=30","first-page":"788","volume":"21","author":"Wei Y.F.","year":"2015","unstructured":"Wei Y.F.; Su J.; Deng Z.L.; Zhu C.; Yuan L.; Lu Z.J.; Zhu Q.Y.; Indirubin inhibits the proliferation of prostate cancer PC-3 cells. Zhonghua Nan Ke Xue  2015,21(9),788-791","journal-title":"Zhonghua Nan Ke Xue"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1021\/acs.jnatprod.6b00285","volume":"79","author":"Gaboriaud-Kolar N.","year":"2016","unstructured":"Gaboriaud-Kolar N.; Myrianthopoulos V.; Vougogiannopoulou K.; Gerolymatos P.; Horne D.A.; Jove R.; Mikros E.; Nam S.; Skaltsounis A.L.; Natural-based indirubins display potent cytotoxicity toward wild-type and t315i-resistant leukemia cell lines. J Nat Prod  2016,79(10),2464-2471","journal-title":"J Nat Prod"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3892\/or.2013.2334","volume":"29","author":"Lee M.Y.","year":"2013","unstructured":"Lee M.Y.; Liu Y.W.; Chen M.H.; Wu J.Y.; Ho H.Y.; Wang Q.F.; Chuang J.J.; Indirubin-3\u2032-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells. Oncol Rep  2013,29(5),2072-2078","journal-title":"Oncol Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1074\/jbc.M115.667436","volume":"291","author":"Barnwal B.","year":"2016","unstructured":"Barnwal B.; Karlberg H.; Mirazimi A.; Tan Y.J.; The non-structural protein of crimean-congo hemorrhagic fever virus disrupts the mitochondrial membrane potential and induces apoptosis. J Biol Chem  2016,291(2),582-592","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-012-1930-3","volume":"40","author":"Chu S.","year":"2013","unstructured":"Chu S.; Liu Y.; Zhang L.; Liu B.; Li L.; Shi J.; Li L.; Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep  2013,40(1),1-6","journal-title":"Mol Biol Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/molecules25092220","volume":"25","author":"Abdalla A.N.","year":"2020","unstructured":"Abdalla A.N.; Abdallah M.E.; Aslam A.; Bader A.; Vassallo A.; Tommasi N.D.; Malki W.H.; Gouda A.M.; Mukhtar M.H.; El-Readi M.Z.; Alkahtani H.M.; Abdel-Aziz A.A.M.; El-Azab A.S.; Synergistic anti leukemia effect of a novel Hsp90 and a pan cyclin dependent kinase inhibitors. Molecules  2020,25(9),2220","journal-title":"Molecules"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/ph15091123","volume":"15","author":"Al-Rawashde F.A.","year":"2022","unstructured":"Al-Rawashde F.A.; Al-wajeeh A.S.; Vishkaei M.N.; Saad H.K.M.; Johan M.F.; Taib W.R.W.; Ismail I.; Al-Jamal H.A.N.; Thymoquinone inhibits JAK\/STAT and PI3K\/Akt\/mTOR signaling pathways in MV4-11 and K562 myeloid leukemia cells. Pharmaceuticals (Basel)  2022,15(9),1123","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13046-018-0880-6","volume":"37","author":"Xiao X.","year":"2018","unstructured":"Xiao X.; Wang W.; Li Y.; Yang D.; Li X.; Shen C.; Liu Y.; Ke X.; Guo S.; Guo Z.; HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res  2018,37(1),201","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206258293231017063340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226849\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715206258293231017063340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T02:12:16Z","timestamp":1714615936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226849\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715206258293231017063340","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}